文献速递腹部泌尿生殖US

评估超声造影LI-RADS 2017版:在非酒精性脂肪性肝炎个体271个肝脏结节中的应用

Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis.
PubMed 文献 · Eur Radiol · 2022-05-31

回顾性纳入2013年1月至2020年12月非酒精性脂肪性肝炎伴未治疗肝脏结节患者,并以2021年1月至8月前瞻性验证集验证,评估超声造影LI-RADS 2017版诊断效能。回顾集217个结节中LR-5对肝细胞癌阳性预测值为70.8%;将动脉期高增强、早期廓清且5分钟内无「穿凿样」表现的LR-M结节重分类为LR-5后,LR-M预测非肝细胞癌恶性肿瘤的特异度由91.0%升至96.5%(p=.023),LR-5特异度和阳性预测值仍高(分别为80.6%和72.5%)。验证集重分类后LR-M特异度由90.0%升至100%(p=.022)。

要点

  • NASH人群中超声造影LR-5诊断肝细胞癌的阳性预测值为70.8%(56/79)。
  • 将动脉期高增强、早期廓清且5分钟内无穿凿样表现的LR-M重分类为LR-5后,LR-M预测非肝细胞癌恶性肿瘤特异度由91.0%(181/199)升至96.5%(192/199),p=.023。
  • 重分类后LR-5特异度和阳性预测值分别为80.6%和72.5%,验证集LR-M特异度由90.0%(45/50)升至100%(50/50),p=.022。

核心结论

  • 超声造影LI-RADS LR-5分类可有效预测肝细胞癌的存在;在NASH患者中,将具有动脉期高增强、早期廓清且呈穿凿样表现的LR-M结节重分类为LR-5可进一步提高诊断效能。

研究设计与样本

  • 回顾性研究纳入2013年1月至2020年12月连续诊断为NASH伴未治疗肝脏结节的患者(211例,217个结节;平均年龄49.7±21.7岁;男性156例),并于2021年1月至2021年8月进行前瞻性验证集评估;评估超声造影LI-RADS 2017版的诊断效能。

诊断标准与关键数值

  • 回顾集LR-5诊断肝细胞癌的阳性预测值为70.8%(56/79);217个结节中28个(12.9%)分类为LR-M,其中12个表现为动脉期高增强、早期廓清且5分钟内无穿凿样表现,这12个中10个(83%)为肝细胞癌;将这些结节重分类为LR-5后,LR-M预测非肝细胞癌恶性肿瘤的特异度由91.0%(181/199)升至96.5%(192/199)(p=.023),LR-5特异度和阳性预测值分别为80.6%和72.5%;验证集重分类后LR-M特异度由90.0%(45/50)升至100%(50/50)(p=.022)。

临床应用与阅片要点

  • 在NASH患者中应用超声造影LI-RADS时,LR-5对肝细胞癌有较高阳性预测值;对于动脉期高增强、早期廓清且5分钟内无穿凿样表现的LR-M结节,重分类为LR-5可提高LR-M预测非肝细胞癌恶性肿瘤的特异度,同时LR-5特异度和阳性预测值仍保持较高水平。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the diagnostic performance of contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS) version 2017 in a population with non-alcoholic steatohepatitis (NASH).

METHODS: Between January 2013 and December 2020, consecutive patients diagnosed with NASH with untreated liver nodules were enrolled in this retrospective study. A prospective evaluation was performed between January 2021 and August 2021 as a validation set. Diagnostic performance was assessed.

RESULTS: We included 217 nodules in 211 patients (mean age, 49.7 ± 21.7 years; male, 156) in the retrospective study. The positive predictive value (PPV) of CEUS LR-5 in the diagnosis of hepatocellular carcinoma (HCC) was 70.8% (56/79). In total, 28 of 217 (12.9%) nodules were classified as LR-M, of which 12 showed arterial phase hyper-enhancement, early washout, and absence of a punched-out appearance within 5 min; 10 of the 12 (83%) were HCC. When these nodules were reclassified as LR-5, the specificity of LR-M as a predictor of non-HCC malignancy increased from 91.0 (181/199) to 96.5% (192/199) (p = .023). Despite the reclassification, LR-5 specificity and PPV remained high (80.6% and 72.5%, respectively). Following reclassification, LR-M specificity increased from 90.0 (45/50) to 100% (50/50) (p = .022) in the validation set.

CONCLUSION: CEUS LI-RADS category LR-5 is effective in predicting the presence of HCC. In NASH patients, diagnostic performance can be further improved by reclassifying LR-M nodules with arterial phase hyper-enhancement, early washout, and punched-out appearance as LR-5.

KEY POINTS: • The LI-RADS classification of CEUS has a high application value for differentiation of HCC in NASH patients. • When LR-M nodules with arterial phase hyperenhancement and early washout but not punched-out appearance at < 5 min are reclassified as LR-5; the modification of LI-RADS has a better performance. • The PPV of modified LR-5 in the non-cirrhotic group was better than that of LR-5. The PPV of modified CEUS LR-5 in the non-cirrhotic group was comparable to that in the cirrhotic group (p both = 0.065).

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Huang, Zhou, Li, et al. Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis. Eur Radiol. 2022. PMID: 35639147. doi:10.1007/s00330-022-08872-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。